{"entity":{"id":"nct03671018","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Mosunetuzumab, Polatuzumab vedotin, Tocilizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT03671018 by Hoffmann-La Roche, with 422 participants planned, started 2018-09-25 and due to reach its primary completion in 2024-01-30. Interventions recorded: Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03671018","url":"https://clinicaltrials.gov/study/NCT03671018"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":["adc","t-cell-engager"],"targets":[],"drugs":["mosunetuzumab","polatuzumab-vedotin","tocilizumab","rituximab"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03671018","phase":"1/2","setting":"An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma","sponsor":"Hoffmann-La Roche","participation":[{"nct":"NCT03671018","source":"https://clinicaltrials.gov/study/NCT03671018","fetchedAt":"2026-10-07T16:53:06.628Z","studySha256":"33fcced9a10bd9e2fee64e9787509f944ed66bae25078e296c377635b4c28bf4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-11-29","leadSponsor":"Hoffmann-La Roche","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":422,"enrolmentType":"ESTIMATED","siteCount":29,"recruitingSiteCount":0,"countries":["Belgium","Canada","Spain","United Kingdom","United States"]}],"started":"2018-09-25","startedType":"actual","enrolled":422,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03671018/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}